Neuropediatrics 2016; 47(03): 179-181
DOI: 10.1055/s-0036-1578798
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Effect of l-Arginine in One Patient with Peroxisome Biogenesis Disorder due to PEX12 Deficiency

Arthur Sorlin
1   Reference Centre for Inborn Errors of Metabolism, University Hospital of Nancy, France
,
Gilbert Briand
2   Laboratory of Hormonology, Metabolism-Nutrition & Oncology (HMNO), Center of Biology and Pathology, CHRU Lille, Lille, France
,
David Cheillan
3   Department of Inborn Errors of Metabolism and of Newborn Screening, Centre de Biologie Est, Hospices Civils de Lyon, Bron, France
4   INSERM U1060, CarMeN Laboratory, University of Lyon, Lyon, France
,
Arnaud Wiedemann
1   Reference Centre for Inborn Errors of Metabolism, University Hospital of Nancy, France
,
Bettina Montaut-Verient
5   Department of Otorhinolaryngology, University Hospital, France
,
Emmanuelle Schmitt
6   Department of Neuroradiology, University Hospital of Nancy, Nancy, France
,
François Feillet
1   Reference Centre for Inborn Errors of Metabolism, University Hospital of Nancy, France
› Author Affiliations
Further Information

Publication History

12 August 2015

07 January 2016

Publication Date:
04 March 2016 (online)

Preview

Abstract

Peroxisome biogenesis disorders (PBD) are a heterogeneous group of disorders due to PEX genes mutations, with a broad clinical spectrum comprising severe neonatal disease to mild presentation. Recently, Berendse et al reported an improvement of peroxisomal functions with l-arginine supplementation in fibroblasts with specific mutations of PEX1, PEX6, and PEX12. We report the first treatment by l-arginine in a patient homozygous for the specific PEX12 mutation shown to be l-arginine responsive in fibroblasts. We described the effect of l-arginine on biochemical (decrease of some plasma peroxisomal parameters) and neurophysiological (improvement of deafness) parameters. Some subjective clinical effects have also been observed (no more sialorrhea, behavior improvement). More studies are needed to assess the efficacy of l-arginine in some PBD patients with specific mutations.